This study provides a critical preclinical validation pathway for the dual blockade strategy of TGF-β and PD-L1, suggesting that in research on immune therapy resistance mechanisms in refractory solid tumors, the GARP-mediated latent activation pathway requires focused attention.
Literature Overview
The article titled "A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors," published in the Journal of Hematology & Oncology, systematically explores the safety, pharmacokinetic characteristics, and preliminary anti-tumor activity of the novel trifunctional bispecific antibody BPB-101 in patients with advanced solid tumors.Background Knowledge
The TGF-β signaling pathway and the PD-1/PD-L1 axis within the tumor microenvironment are two core mechanisms of immune suppression. While current bispecific antibody strategies can simultaneously block PD-L1 and sequester TGF-β, they often struggle to address the complex biological characteristics of TGF-β, particularly its conversion from the latent complex (SLC) to the active form. As a key surface receptor, GARP assists αV integrin in mechanically releasing active TGF-β. This mechanism allows drugs that only neutralize active TGF-β to be bypassed by continuously secreted latent precursors. Therefore, how to simultaneously block the GARP-dependent activation pathway and neutralize existing active TGF-β has become a critical pain point in addressing immune-excluded tumors. The design of BPB-101 aims to overcome this bottleneck by targeting the GARP/TGF-β complex, active TGF-β, and PD-L1, achieving synergistic blockade of dual immune suppression mechanisms.
Research Methods and Core Experiments
This study employed an accelerated titration design combined with a standard 3+3 dose-escalation scheme to evaluate BPB-101 in 19 patients with advanced solid tumors who had previously received standard systemic therapy and had no other treatment options. The study covered multiple dose groups ranging from 6 mg to 1800 mg, with intravenous administration every 3 weeks. Key evidence was derived from the assessment of dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended Phase II dose (RP2D), combined with pharmacokinetic (PK) and pharmacodynamic (PD) analyses. The study utilized flow cytometry to detect receptor occupancy (RO) of PD-L1 and the GARP/TGF-β complex in peripheral blood and monitored changes in circulating TGF-β1 levels to verify the drug's target binding capability in vivo.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides important clinical data support for the application of trifunctional antibodies in the treatment of solid tumors. The successful validation of BPB-101 indicates that fine-tuned regulation of the TGF-β activation mechanism (i.e., simultaneous targeting of both latent and active forms) may offer advantages over single-blockade strategies. Future drug development should focus on expanded cohort studies in specific tumor types (such as ovarian cancer and nasopharyngeal carcinoma) to further explore the correlation between biomarkers and efficacy. Additionally, these findings suggest that in clinical monitoring, peripheral blood TGF-β levels and receptor occupancy can serve as effective surrogate endpoints for assessing drug activity.
Conclusion
As the world's first trifunctional antibody targeting the GARP/TGF-β complex, active TGF-β, and PD-L1, the results of the first-in-human Phase Ia study of BPB-101 are encouraging. This study not only confirmed the safety and favorable pharmacokinetic profile of the drug in patients with advanced solid tumors but, more importantly, successfully overcame the limitations of traditional TGF-β inhibitors in completely blocking latent activation through its unique "dual-pronged" mechanism. For patients with refractory solid tumors, particularly those who have developed resistance to single immune checkpoint inhibitors, BPB-101 has demonstrated preliminary anti-tumor activity, laying a solid foundation for subsequent clinical development. This discovery not only enriches the arsenal of tumor immunotherapy drugs but also provides a new perspective for understanding the complex regulatory network of TGF-β in the tumor microenvironment, potentially driving the further application of precision medicine strategies in complex tumor microenvironments.
